Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sirnaomics Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2257)

(1) GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS AND (2) CONDITIONAL GRANT OF RESTRICTED SHARE UNITS TO A DIRECTOR

This announcement is made by the Company pursuant to Rules 17.06A, 17.06B and 17.06C of the Listing Rules.

The Board announces that on October 29, 2026, the Company granted 893,647 Share Options to 25 Share Option Grantees (the "**Share Option Grants**"), granted 2,048,814 RSUs to 27 RSU Grantees (excluding Dr. Poon) (the "**RSU Grants**") and conditionally granted 1,000,000 RSUs to Dr. Poon (the "**Connected RSU Grant**") in accordance with the terms of the 2026 Share Option Scheme and 2026 RSU Scheme, respectively, subject to acceptance by the Share Option Grantees, the RSU Grantees and Dr. Poon.

GRANT OF SHARE OPTIONS

The details of the Share Option Grants are as follows:

Grant Date:	October 29, 2026
Number of Share Option Grantee(s):	25
Number of Share Options granted:	893,647

Consideration for the Share Option Grants:	HK$1.00 to be paid by each Share Option Grantee upon acceptance of the Share Options granted
Exercise price of the Share Options granted:	HK$4.13 per Share The exercise price of the Share Options of HK$4.13 per Share represents the highest of (i) the closing price of the Shares of HK$4.13 per Share as stated in the daily quotation sheet issued by the Stock Exchange on the Grant Date, (ii) the average closing price of the Shares of HK$4.06 per Share as stated in the daily quotation sheets issued by the Stock Exchange for the five business days immediately preceding the Grant Date, or (iii) the nominal value of each Share, which is US$0.001.
Exercise period of the Share Options:	The exercise period of the Share Options shall be 10 years from the Grant Date.
Vesting period:	All Share Options granted to the Share Option Grantees shall vest in the Share Option Grantees as follows: (i) 50% shall vest on the first anniversary of the Grant Date; and (ii) 50% shall vest on the second anniversary of the Grant Date.
Performance targets:	The Share Options are time-vesting with no performance targets attached. The purpose of the 2026 Share Option Scheme is to attract and retain the participants of the 2026 Share Option Scheme whose contributions are important to the long-term growth and success of the Group, to recognize and reward the participants for their past contribution to the Group, to provide the participants with the opportunity to acquire proprietary interests in the Company and to encourage the participants to further contribute to the Company and work towards enhancing the value of the Company and its Shares for the benefit of the Company and its Shareholders as a whole.

Having considered that (i) the Share Option Grantees are employees of the Group who have contributed and will continue to contribute significantly to the overall business performance, sustainable development and/or good corporate governance of the Group; (ii) the Share Option Grants are in recognition of the past contributions of the Share Option Grantees to the Group; and (iii) the Share Options granted to the Share Option Grantees will be vested in two tranches over a period of two years from the Grant Date, the Remuneration Committee is of the view that the Share Option Grants without performance targets are market competitive, consistent with the Company's remuneration policy and customary practice, and will align the interests of the Share Option Grantees with those of the Company and the Shareholders, motivate them to work towards successes of the Group and reinforce their commitment to the long-term service of the Group, which is in line with the purpose of the 2026 Share Option Scheme.

Clawback mechanism:

The Share Options granted shall be subject to the clawback mechanism as set out in the terms of the 2026 Share Option Scheme, including but not limited to circumstances where (i) a Share Option Grantee has been convicted of a criminal offence involving his/her integrity or honesty; or (ii) in the reasonable opinion of the Board, a Share Option Grantee has engaged in serious misconduct or has breached the terms of the 2026 Share Option Scheme or the offer letter for the Share Option Grants in any material respect.

The Share Options that are clawback will be regarded as cancelled and as utilised for the purpose of calculating the Scheme Mandate Limit.

Financial Assistance:

The Group has not provided any financial assistance to the Share Option Grantees for the purchase of Shares under the 2026 Share Option Scheme.

GRANT OF RESTRICTED SHARE UNITS

Details of the RSU Grants are as follows:

Grant Date:	October 29, 2026
Number of RSU Grantee(s):	27
Number of RSUs granted:	2,048,814 RSUs to 27 employees of the Group Each of the RSUs granted to the RSU Grantees represents a right to receive a Share on the date the RSU vests
Consideration for the RSU Grants:	Nil
Closing price of the Shares on the Grant Date:	HK$4.13 per Share
Vesting period:	The total vesting period for the RSUs granted to the RSU Grantees (i.e. the period between the Grant Date and the last vesting date) is 24 months, where the RSUs may vest by two tranches: (i) 50% of the RSUs granted shall be vested on the first anniversary of the Grant Date; and (ii) 50% of the RSUs granted shall be vested on the second anniversary of the Grant Date.
Performance targets:	The RSUs are time-vesting with no performance targets attached. The purpose of the 2026 RSU Scheme is to attract and retain the participants of the 2026 RSU Scheme whose contributions are important to the long-term growth and success of the Group, to recognize and reward the participants for their past contribution to the Group, to provide the participants with the opportunity to acquire proprietary interests in the Company and to encourage the participants to further contribute to the Company and work towards enhancing the value of the Company and its Shares for the benefit of the Company and its Shareholders as a whole.

	Having considered that (i) the RSU Grantees are employees of the Group who have contributed and will continue to contribute significantly to the overall business performance, sustainable development and/or good corporate governance of the Group; (ii) the RSU Grants are in recognition of the past contributions of the RSU Grantees to the Group; and (iii) the RSUs granted to the RSU Grantees will be vested in two tranches over a period of two years from the Grant Date, the Remuneration Committee is of the view that the RSU Grants without performance targets are market competitive, consistent with the Company's remuneration policy and customary practice, and will align the interests of the RSU Grantees with those of the Company and the Shareholders, motivate them to work towards successes of the Group and reinforce their commitment to the long term service of the Group, which is in line with the purpose of the 2026 RSU Scheme.
Clawback mechanism:	The RSUs granted shall be subject to the clawback mechanism as set out in the terms of the 2026 RSU Scheme, pursuant to which the Board may, in its sole and absolute discretion, determine that any RSUs granted but not yet vested shall immediately lapse where, among others, the RSU Grantee materially violates his/her obligations of confidentiality or non-competition to the Group, or materially breaches any internal policy or code of any Group company or the terms of the 2026 RSU Scheme.

GRANT OF RESTRICTED SHARE UNITS TO A DIRECTOR

Details of the Connected RSU Grant are as follows:

Grant Date:	October 29, 2026
Number of RSU grantee:	1
Number of RSUs conditionally granted:	1,000,000 RSUs to Dr. Poon
Consideration for the Connected RSU Grant:	Nil

Closing price of the Shares on the Grant Date:	HK$4.13 per Share
Conditions precedent for the Connected RSU Grant:	The Connected RSU Grant to Dr. Poon is conditional upon the Company obtaining the approval of the independent Shareholders at the EGM in accordance with Rules 17.04(2) and 17.04(3) of the Listing Rules
Vesting period:	The total vesting period for the RSUs conditionally granted to Dr. Poon (i.e. the period between the Grant Date and the last vesting date) is 24 months, where the RSUs may vest by two tranches: (i) 50% of the RSUs granted shall be vested on the first anniversary of the Grant Date; and (ii) 50% of the RSUs granted shall be vested on the second anniversary of the Grant Date.
Performance targets:	The RSUs are time-vesting with no performance targets attached. Same as set out in the section headed "Grant of Restricted Share Units — Performance targets" in this announcement.
Clawback mechanism:	Same as set out in the section headed "Grant of Restricted Share Units — Clawback mechanism" in this announcement.

REASONS FOR AND BENEFITS OF THE SHARE OPTION GRANTS, THE RSU GRANTS AND THE CONNECTED RSU GRANT

The purposes of the aforesaid Share Option Grants, RSU Grants and Connected RSU Grant are (a) to further establish and improve the long-term incentive and restraint mechanism of the Company to attract and retain outstanding employees; (b) to fully motivate the management and core personnel of the Company; and (c) to effectively align the interests of Shareholders, the Company and the personal interests of employees so that all parties can focus on the long-term development of the Company.

In particular, in relation to the conditional grant of 1,000,000 RSUs to Dr. Poon, Dr. Poon has served as an executive Director and the chief executive officer of the Company since 2024 and has been continuously responsible for the Group's overall strategic planning and

business decisions. His leadership has been instrumental to the development and success of the Group. Under his leadership, the Group is advancing its clinical pipeline, expanding its global reach, and communicating its strengths to the market with clarity and transparency.

The Group requires a core leader with exceptional leadership capabilities to oversee overall strategy and development, drive the advancement of medium to long-term businesses, and ensure the achievement of all operational objectives. It is anticipated that under the leadership of Dr. Poon, the corporate value of the Group will be further enhanced, thereby safeguarding and promoting the interests of the Company and all its Shareholders as a whole.

SHARES AVAILABLE FOR FUTURE GRANT UNDER THE 2026 SHARE OPTION SCHEME AND THE 2026 RSU SCHEME

The maximum number of new Shares that may be issued pursuant to all options and awards granted or to be granted under the 2026 Share Option Scheme and the 2026 RSU Scheme is 10,972,153 Shares, with the Scheme Mandate Limit being 10% of the total issued and outstanding Shares (excluding any treasury shares) as at the date of the shareholders' approval of the 2026 Share Option Scheme and the 2026 RSU Scheme on June 30, 2026. As of the date of this announcement (after taking into account the Share Option Grants, the RSU Grants and the Connected RSU Grant), 7,029,692 Shares are available for future grants under the Scheme Mandate Limit.

The Company has established a trust arrangement in connection with the administration of its Share Schemes, including the 2026 Share Option Scheme and the 2026 RSU Scheme, to facilitate the efficient management of options and/or awards granted to eligible participants across multiple jurisdictions. The Company has engaged a professional Trustee to hold and manage the underlying Shares to be issued under the Share Schemes. As at the date of this announcement, 9,848,172 underlying Shares are held by the Trustee, and no new shares will be issued. Accordingly, the grants will not result in any dilution of the shareholdings of the Company's existing Shareholders.

LISTING RULES IMPLICATIONS

The 2026 Share Option Scheme and 2026 RSU Scheme shall be subject to Chapter 17 of the Listing Rules.

Connected RSU Grant

Dr. Poon is an executive Director, the chairman of the Board, the chief executive officer and a substantial shareholder of the Company. Pursuant to Rule 17.04(1) of the Listing Rules and the terms of the 2026 RSU Scheme, any grant of options or awards to a director, chief executive or substantial shareholder of a listed issuer, or any of their respective

associates, under a scheme of the listed issuer must be approved by the independent non-executive directors of the listed issuer (excluding any independent non-executive director who is the grantee of the options or awards). The Connected RSU Grant has been reviewed and approved by the independent non-executive Directors in accordance with Rule 17.04(1) of the Listing Rules and the terms of the 2026 RSU Scheme.

Pursuant to Rules 17.04(2), 17.04(3) and 17.04(4) of the Listing Rules and the terms of the 2026 RSU Scheme, where any grant of awards (excluding grant of options) to a director (other than an independent non-executive director) or chief executive of the issuer, or any of their associates, or grant of options or awards to an independent non-executive director or substantial shareholder, or any of their respective associates, would result in the shares issued and to be issued in respect of the relevant awards or options granted to such person in the 12-month period up to and including the date of such grant, representing in aggregate over 0.1% of the relevant class of shares in issue (excluding treasury shares), such further grant must be approved by shareholders of the listed issuer in general meeting. The grantee, his/her associates and all core connected persons of the listed issuer must abstain from voting in favor at such meeting.

As the 1,000,000 RSUs conditionally granted to Dr. Poon represent approximately 0.89% of the issued Shares (excluding treasury shares) as at the Grant Date, which exceeds the 0.1% threshold under Rules 17.04(2) and 17.04(3) of the Listing Rules, the Connected RSU Grant is conditional upon the approval of the independent Shareholders at the Extraordinary General Meeting, with Dr. Poon, his associates and all core connected persons of the Company abstaining from voting in favor. An ordinary resolution will be proposed at the Extraordinary General Meeting to consider and, if thought fit, approve the Connected RSU Grant. A circular containing, inter alia, further details of the Connected RSU Grant and the information required by the Listing Rules, together with the notice of the Extraordinary General Meeting, will be despatched to the Shareholders in due course.

Share Option Grants and RSU Grants

Save as disclosed above, as at the date of this announcement, to the best knowledge, information and belief of the Directors, having made all reasonable enquiries, none of the Share Option Grantees or the RSU Grantees is (i) a Director, chief executive or substantial shareholder of the Company or any of their respective associates (as defined in the Listing Rules); (ii) a participant to whom the grants of options or awards during the 12-month period up to and including the Grant Date would result in the relevant 1% individual limit under Rule 17.03D of the Listing Rules being exceeded; or (iii) a related entity participant or service provider (as defined in the Listing Rules) who is not an eligible participant under

the 2026 Share Option Scheme or the 2026 RSU Scheme. Accordingly, the Share Option Grants and the RSU Grants are not subject to the approval requirements under Rules 17.04(1), 17.04(2), 17.04(3), 17.04(4) or 17.03D of the Listing Rules.

DEFINITIONS

"2026 Share Option Scheme"	the share option scheme adopted by the Company on June 30, 2026
"2026 RSU Scheme"	the restricted share unit scheme adopted by the Company on June 30, 2026
"associates"	has the meaning ascribed to it under the Listing Rules
"Award(s)"	an award of RSU(s) granted or to be granted by the Board in accordance with the terms of the 2026 RSU Scheme
"Board"	the board of directors of the Company
"chief executive(s)"	has the same meaning ascribed to it under the Listing Rules
"Company"	Sirnaomics Ltd., an exempted company incorporated in the Cayman Islands with limited liability on October 15, 2020
"connected person(s)"	has the same meaning ascribed to it under the Listing Rules
"Connected RSU Grant"	the conditional grant of 1,000,000 RSUs to Dr. Poon in accordance with the 2026 RSU Scheme on the Grant Date, subject to the approval of the independent Shareholders at the EGM
"core connected person(s)"	has the same meaning ascribed to it under the Listing Rules
"Director(s)"	director(s) of the Company
"Dr. Poon"	Dr. Poon Hung Fai, an executive Director, the chairman of the Board, the chief executive officer of the Company and a substantial shareholder of the Company
"Extraordinary General Meeting" or "EGM"	the extraordinary general meeting to be convened by the Company
"Grant Date"	October 29, 2026

"Group"	the Company, its subsidiaries or, where the context so requires, in respect of the period prior to the Company becoming the holding company of its present subsidiaries, such subsidiaries as if they were subsidiaries of the Company at the relevant time
"HK$"	Hong Kong dollars, the lawful currency of Hong Kong
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange
"Remuneration Committee"	the remuneration committee of the Board
'RSU(s)"	restricted share units granted or to be granted under the 2026 RSU Scheme
"RSU Grantees"	the 27 employees of the Group (excluding Dr. Poon) who were granted RSUs in accordance with the 2026 RSU Scheme on the Grant Date
"RSU Grants"	the grants of an aggregate of 2,048,814 RSUs to 27 RSU Grantees in accordance with the terms of the 2026 RSU Scheme on the Grant Date
"Scheme Mandate Limit"	the total number of Shares that may be issued or transferred upon exercise of all Share Options to be granted under the 2026 Share Option Scheme, Awards to be granted under the 2026 RSU Scheme and all options and awards to be granted under any other Share Schemes of the Group shall not in aggregate exceed 10% of the Shares in issue (excluding treasury shares) as at June 30, 2026
"Share(s)"	ordinary share(s) in the share capital of the Company with a par value of US$0.001 each
"Share Option(s)"	the share option(s) to subscribe or acquire for Share(s) under the 2026 Share Option Scheme
"Share Option Grants"	the grants of an aggregate of 893,647 Share Options to 25 Share Option Grantees in accordance with the terms of the 2026 Share Option Scheme

''Share Option Grantees''	the employees of the Group who were granted Share Options in accordance with the 2026 Share Option Scheme on the Grant Date
''Shareholder(s)''	the holder(s) of the Share(s)
''Share Scheme(s)''	share options schemes and/or share award schemes adopted and to be adopted by the Company from time to time
''Stock Exchange''	The Stock Exchange of Hong Kong Limited
''subsidiary(ies)''	has the meaning ascribed thereto under the Listing Rules
''substantial shareholder(s)''	has the meaning ascribed thereto under the Listing Rules
''Trust Deed''	the trust deed entered into between the Company (as the settlor) and the Trustee (as the trustee) in relation to the appointment of the Trustee to administer the relevant Share Scheme (as restated, supplemented and amended from time to time)
''Trustee''	Maples Trustee Services (Cayman) Limited, being a third party independent of the Company and its connected persons, which is the trustee appointed by the Company pursuant to the Trust Deed to administer the relevant Share Scheme
''US$''	U.S. dollars, the lawful currency of the United States of America
''%''	per cent

By order of the Board
Sirnaomics Ltd.
Dr. Poon Hung Fai
Chairman and Executive Director

Hong Kong, October 29, 2026

As at the date of this announcement, the Board comprises Dr. Poon Hung Fai as executive Director, Dr. Yin Huijun as non-executive Director, and Mr. Wong Yu Shan Eugene, Dr. Zhang Peng and Ms. Lo Yee Hang as independent non-executive Directors.